EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
JAN 2022
TABLES
123
PAGES
184
EDITION
7
PRICE
USD 4950
CODE
MCP13016
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
Global Lifestyle Drugs Market to Reach $36.4 Billion by 2026
Amid the COVID-19 crisis, the global market for Lifestyle Drugs estimated at US$30.7 Billion in the year 2020, is projected to reach a revised size of US$36.4 Billion by 2026, growing at a CAGR of 2.8% over the analysis period. Depression, one of the segments analyzed in the report, is projected to record a 2.4% CAGR and reach US$8.2 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Dermatology segment is readjusted to a revised 2.6% CAGR for the next 7-year period.
The U.S. Market is Estimated at $9.3 Billion in 2021, While China is Forecast to Reach $6.5 Billion by 2026
The Lifestyle Drugs market in the U.S. is estimated at US$9.3 Billion in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.5 Billion by the year 2026 trailing a CAGR of 2.7% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.5% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.
Sexual Dysfunction Segment to Reach US$4.2 Billion by the year 2026
In the global Sexual Dysfunction segment, USA, Canada, Japan, China and Europe will drive the 2.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$2.8 Billion in the year 2020 will reach a projected size of US$3.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
SELECT PLAYERS
Alembic Pharmaceuticals Limited; Amgen, Inc.; AstraZeneca PLC; Biocon Ltd.; Cipla Ltd.; Dr. Reddy's Laboratories Ltd.; Eli Lilly and Company; GlaxoSmithKline PLC; Johnson & Johnson; Lupin Ltd.; Merck & Co., Inc.; Mylan Pharmaceuticals, Inc.; Novo Nordisk A/S; Pfizer, Inc.; Piramal Enterprises Limited; Procter & Gamble Company, The; Sun Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd.; Zydus Cadila
SEGMENTS
» Therapy Area (Depression, Dermatology, Sexual Dysfunction, Obesity)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Impact of Covid-19 and a Looming Global Recession |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
4. GLOBAL MARKET PERSPECTIVE |
World Current & Future Analysis for Lifestyle Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Lifestyle Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Lifestyle Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Depression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Depression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Depression by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Dermatology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Dermatology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Dermatology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Sexual Dysfunction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Sexual Dysfunction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Sexual Dysfunction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Obesity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Obesity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Obesity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
III. MARKET ANALYSIS |
UNITED STATES |
USA Current & Future Analysis for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Lifestyle Drugs by Therapy Area - Percentage Breakdown of Value Sales for Depression, Dermatology, Sexual Dysfunction and Obesity for the Years 2012, 2020 & 2027 |
CANADA |
Canada Current & Future Analysis for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Lifestyle Drugs by Therapy Area - Percentage Breakdown of Value Sales for Depression, Dermatology, Sexual Dysfunction and Obesity for the Years 2012, 2020 & 2027 |
JAPAN |
Japan Current & Future Analysis for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Lifestyle Drugs by Therapy Area - Percentage Breakdown of Value Sales for Depression, Dermatology, Sexual Dysfunction and Obesity for the Years 2012, 2020 & 2027 |
CHINA |
China Current & Future Analysis for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
China Historic Review for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Lifestyle Drugs by Therapy Area - Percentage Breakdown of Value Sales for Depression, Dermatology, Sexual Dysfunction and Obesity for the Years 2012, 2020 & 2027 |
EUROPE |
Europe Current & Future Analysis for Lifestyle Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
Europe Historic Review for Lifestyle Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Lifestyle Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
Europe Current & Future Analysis for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Lifestyle Drugs by Therapy Area - Percentage Breakdown of Value Sales for Depression, Dermatology, Sexual Dysfunction and Obesity for the Years 2012, 2020 & 2027 |
FRANCE |
France Current & Future Analysis for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
France Historic Review for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Lifestyle Drugs by Therapy Area - Percentage Breakdown of Value Sales for Depression, Dermatology, Sexual Dysfunction and Obesity for the Years 2012, 2020 & 2027 |
GERMANY |
Germany Current & Future Analysis for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Lifestyle Drugs by Therapy Area - Percentage Breakdown of Value Sales for Depression, Dermatology, Sexual Dysfunction and Obesity for the Years 2012, 2020 & 2027 |
ITALY |
Italy Current & Future Analysis for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Lifestyle Drugs by Therapy Area - Percentage Breakdown of Value Sales for Depression, Dermatology, Sexual Dysfunction and Obesity for the Years 2012, 2020 & 2027 |
UNITED KINGDOM |
UK Current & Future Analysis for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Lifestyle Drugs by Therapy Area - Percentage Breakdown of Value Sales for Depression, Dermatology, Sexual Dysfunction and Obesity for the Years 2012, 2020 & 2027 |
REST OF EUROPE |
Rest of Europe Current & Future Analysis for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Lifestyle Drugs by Therapy Area - Percentage Breakdown of Value Sales for Depression, Dermatology, Sexual Dysfunction and Obesity for the Years 2012, 2020 & 2027 |
ASIA-PACIFIC |
Asia-Pacific Current & Future Analysis for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Lifestyle Drugs by Therapy Area - Percentage Breakdown of Value Sales for Depression, Dermatology, Sexual Dysfunction and Obesity for the Years 2012, 2020 & 2027 |
REST OF WORLD |
Rest of World Current & Future Analysis for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of World Historic Review for Lifestyle Drugs by Therapy Area - Depression, Dermatology, Sexual Dysfunction and Obesity Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of World 15-Year Perspective for Lifestyle Drugs by Therapy Area - Percentage Breakdown of Value Sales for Depression, Dermatology, Sexual Dysfunction and Obesity for the Years 2012, 2020 & 2027 |
IV. COMPETITION |
Total Companies Profiled: 22 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com